Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: Current concepts and perspectives

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 5, 1997, Pages 479-488

  Ravandi Kashani, Farhad ^a   Schafer, Andrew I ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiplatelet therapy; Cytoreductive therapy; Essential thrombocythemia; Thromhosis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; HYDROXYUREA; PHOSPHORUS 32; RECOMBINANT ALPHA INTERFERON;

ARTICLE; BLEEDING; CLINICAL EXAMINATION; DRUG EFFICACY; DRUG RESEARCH; HUMAN; MICROVASCULATURE; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0030773518     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996125     Document Type: Article

References (112)

1. Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1-12, 1984.
2. Schafer AI: Essential thrombocythemia. Prog Hemost Thromb 10:69-96, 1991.
3. Rozman C, M Giralt, E Feliu, et al: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663, 1991.
4. Taft EG, RB Babcock, WB Scharman, et al: Plateletpheresis in the management of thrombocytosis. Blood 50:927-933, 1977.
5. Younger J, J Umlas: Rapid reduction of platelet count in essential hemorrhagic thrombocythemia by discontinuous flow platelet-pheresis. Am J Med 64:659-661, 1978.
6. Orlin JB, EM Berkman: Improvement of platelet function following plateletpheresis in patients with myeloproliferative disease. Transfusion 20:540-545, 1980.
7. Fialkow PJ, GB Faguet, RJ Jacobsen, et al: Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent cell. Blood 58:916-919, 1981.
8. Knuutila S, T Ruutu, S Partanen, et al: Chromosome 1q+ in erythroid and granulocyte-monocyte precursors in a patient with essential thrombocythemia. Cancer Genet Cytogenet 9:245-249, 1983.
9. Lucas GS, RA Padua, GS Masters, et al: The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease. Br J Haematol 72:530-533, 1989.
10. Blanchard KL, DG Gilliland, HF Bunn: Clonality in myeloproliferative disorders. Am J Med Sci 304:125-130, 1992.
11. Tsukamoto N, K Morita, T Maehara, et al: Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 86:253-258, 1994.
12. Harker LA, CA Finch: Thrombokinetics in man. J Clin Invest 48:963-974, 1969.
13. Branehog I, B Ridell, B Swolin, et al: Megakaryocyte quantifications in relation to thrombokinetics in primary thrombocythemia and allied diseases. Scand J Haematol 15:321-332, 1975.
14. Vainchenker W, J Bouguet, J Guichard, et al: Megakaryocyte colony formation from human bone marrow precursors. Blood 59:940-945, 1979.
15. Mazur EM, R Hoffman, E Bruno: Regulation of human megakaryocytopoiesis. An in-vitro analysis. J Clin Invest 68:733-741, 1981.
16. Messner HA, N Jamal, C Izaguirre: The growth of large human megakaryocyte colonies from human bone marrow. J Cell Physiol (suppl 1):45-51, 1982.
17. Solberg LA, N Jamal, NA Messner: Characterization of human megakaryocytic colony formation in human plasma. J Cell Physiol 124:67-74, 1985.
18. Ash RC, D Llindquist, RP McEver, et al: Differential erythroid and megakaryocytic progenitor cell growth in vitro as a diagnostic discriminant in myeloproliferative disorders. Clin Res 30:310 (Abst), 1982.
19. Gewirtz AM, E Bruno, J Elwell, et al: In vitro studies of megakaryocytopoiesis in thrombocytotic disorders of man. Blood 61:384-389, 1983.
20. Komatsu N, T Suda, Y Sakata, et al: Megakaryocytopoiesis in vitro of patients with essential thrombocythaemia: effect of plasma and serum on megakaryocytic colony formation. Br J Haematol 64:241-252, 1986.
21. Mazur EM, JL Cohen, L Bogart: Growth characteristics of circulating hematopoietic progenitor cells from patients with essential thrombocythemia. Blood 71:1544-1550, 1988.
22. Han ZC, J Briere, JF Abgrall, et al: Spontaneous formation of megakaryocyte progenitors (CFU-MK) in primary thrombocythaemia. Acta Haematol 78:51-53, 1987.
23. Juvonen E, S Partanen, T Ruutu: Colony formation by megakaryocytic progenitors in essential thrombocythemia. Br J Haematol 66:161-164, 1987.
24. Kimura H, T Ishibashi, T Sato, et al: Megakaryocytic colony formation (CFU-Meg) in essential thrombocythemia: quantitative and qualitative abnormalities of bone marrow CFU-Meg. Am J Hematol 24:23-30, 1987.
25. Eridani S, JM Dudley, BM Sawyer, et al: Erythropoietic colonies in a serum-free system: results in primary proliferative polycythaemia and thrombocythaemia. Br J Haematol 67:387-391, 1987.
26. Eridani S, B Sawyer, TC Pearson: Patterns of in vitro BFU-E proliferation in different forms of polycythaemia and in thrombocythaemia. Eur J Haematol 38:363-369, 1987.
27. Griesshammer M, H Schrezenmeier, M Bangerter, et al: A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia. Semin Thromb Hemost 23:419-423, 1997.
28. Tefferi A, MN Silverstein, HC Hoagland: Primary thrombocythemia. Semin Oneol 22:334-340, 1995.
29. Michiels JJ, E Juvonen: Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 23:339-347, 1997.
30. Burkhardt R, R Bartl, K Jager, et al: Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings. J Clin Pathol 39:237-252, 1986.
31. Thiele J, G Schneider, B Hoeppner, et al: Histomorphometry of hone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis - features of significance lor the diagnosis of primary (essential) thrombocythaemia. Virchows Arch A Pathol Anat Histopathol 413:407-417, 1988.
32. Wolf BC, RS Neiman: The bone marrow in myeloproliferative and dysmyelopoietic syndromes. Haematol Oncol Clin North Am 2:669-694, 1988.
33. Third international workshop on chromosomes in leukemia, 1980: Report on essential thrombocythemia. Cancer Genet Cytogenet 4:138-142, 1981.
34. Juvonen H, H Ikkala, K Oksanen, et al: Megakaryocyte and erythroid colony formation in essential thrombocythemia and reactive thrombocytosis: Diagnostic value and correlation to complications. Br J Haematol 83:192-197, 1993.
35. Florensa L, C Besses, S Woessner, et al: Endogenous megakaryocyte and erythroid colony formation from blood in essential thromhocythaemia. Leukemia 9:271-273, 1995.
36. Han ZC, J Briere, JF Abgrall, et al: Characteristics of megakaryocyte colony formation in normal individuals and in primary thrombocythemia: studies using an optimal cloning system. Exp Hematol 17:46-52, 1989.
37. Rolovic Z, N Basara, M Gotic, et al: The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. Br J Haematol 90:326-331, 1995.
38. Linch DC, R Hutton, D Cowan, et al: Primary thrombocythaemia in childhood. Scand J Haematol 28:72-76, 1982.
39. Eyster ME, SL Saletan, EM Rabellino, et al: Familial essential thrombocythemia. Am J Med 80:497-502, 1986.
40. Reisner SA, D Rinkevich, W Markiewicz, et al: Cardiac involvement in patients with myeloproliferative disorders. Am J Med 93:498-504, 1992.
41. Randi ML, F Stocco, C Rossi, et al: Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med 22:213-223, 1991.
42. Arboix A, C Besses, P Acin, et al: Ischemic stroke as first manifestation of essential thrombocythemia. Report of six cases. Stroke 26:1463-1466, 1995.
43. Johnson M, T Gernsheimer, K Johansen: Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. J Vasc Surg 22:443-449, 1995.
44. van Genderen PJ, JJ Michiels, R van Strik, et al: Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal hy aspirin. Thromb Haemost 73:210-214, 1995.
45. Pearson TC: Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost, 23:433-439, 1997.
46. Santos MT, J Valles, J Aznar, et al: Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 95:63-68, 1997.
47. Mitchell SW: On a rare vasomotor neurosis of the extremities, and on the maladies with which it may be confounded. Am J Med Sci 76:2, 1878.
48. Babb RR, D Alarcon-Segovia, JF Fairbairn II: Erythromelalgia: review of 51 cases. Circulation 29:136-141, 1964.
49. Michiels JJ, J Abels, J Steketee, et al: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471, 1985.
50. Kurzrock R, PR Cohen: Erythromelalgia: review of clinical characteristics and pathophysiology. Am J Med 91:416-422, 1991.
51. Michiels JJ, FWJ ten Kate, VD Vuzevski, et al: Histopathology of erythromelalgia in thrombocythaemia. Histopathology 8:669-678, 1984.
52. Redding KG: Thrombocythemia as a cause of erythromelalgia. Arch Dermatol 113:468-471, 1977.
53. van Genderen PJJ, JJ Michiels: Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost, 23:357-363, 1997.
54. Singh AK, G Wetherley-Mein: Microvascular occlusive lesions in primary thrombocythaemia. Br J Haematol 36:553-564, 1977.
55. Preston FE, IG Emmanuel, DA Winfield, et al: Essential thrombocythaemia and peripheral gangrene. Br Med J 3:548-552, 1974.
56. Preston FE: Essential thrombocythaemia (letter). Lancet 1:1021, 1982.
57. Michiels JJ: Erythromelalgia and thrombocythemia. A disease of platelet prostaglandin metabolism. Thesis 1981, Rotterdam. Semin Thromb Hemost 23:335-338, 1997.
58. Levine J, PD Swanson: Idiopathic thrombocytosis. A treatable cause of transient ischemic attacks. Neurology 18:711-713, 1968.
59. Korenman G: Neurologic syndromes associated with primary thrombocythemia. J Mt Sinai Hosp 36:317-323, 1969.
60. Jabaily J, HJ Iland, J Laszlo, FJ Fernandez-Debora, et al: Neurologic manifestations of essential thrombocythemia. Ann Intern Med 99:513-518, 1983.
61. Hehlmann R, M Jahn, B Baumann, et al: Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 61:2487-2496, 1988.
62. Lahuerta-Palacios JJ, R Bornstein, FJ Fernandez-Debora, et al: Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 61:1207-1212, 1988.
63. Michiels JJ, PJ Koudstaal, AH Mulder, et al: Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 43:1107-1110, 1993.
64. Koudstaal PJ, A Koudstaal: Neurological and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. Semin Thromb Hemost 23:365-370, 1997.
65. Falconer J, G Pineo, W Blahey, et al: Essential thrombocythemia associated with recurrent abortions and fetal growth retardation. Am J Hematol 25:345-347, 1987.
66. Mercer B, J Drouin, E Jolly, et al: Primary thrombocythemia in pregnancy: a report of two cases. Am J Obstet Gynecol 159: 127-128, 1988.
67. Snethlage W, JW Ten Cate: Thrombocythaemia and recurrent late abortions: normal outcome of pregnancies after antiaggregatory treatment. Case report. Br J Obstet Gynaecol 93:386-388, 1986.
68. Bellucci S, M Janvier, G Tobelem, et al: Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 58:2440-2447, 1986.
69. Jones EC, MW Mosesson, JL Thomason, et al: Essential thrombocythemia in pregnancy. Obstet Gynecol 71:501-503, 1988.
70. Sanada M: Three successful pregnancies in a woman with essential thrombocythemia (letter). Eur J Haematol 42:215-216, 1989.
71. Beressi AH, A Tefferi, MN Silverstein, et al: Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 155:1217-1222, 1995.
72. Valla D, N Casadevall, C Lacombe, et al: Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 103:329-334, 1985.
73. Valla D, N Casadevall, MG Huisse, et al: Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 94:1063-1069, 1988.
74. De Stefano V, L Teofili, G Leone, et al: Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 23:411-418, 1997.
75. Schafer AI: The primary and secondary hypercoagulable states. In: Schafer AI (ed): Molecular Mechanisms of Hypercoagulable States. Landes, Austin, 1997, pp 1-48.
76. Kaywin P, M McDonough, PA Insel, et al: Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet α-adrenergic receptors. N Engl J Med 299:505-509, 1978.
77. Barbui T, R Battista, E Dini: Spontaneous platelet aggregation in myeloproliferative disorders: a preliminary study. Acta Haematol 50:25-29, 1973.
78. Wu KK: Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 88:7-11, 1978.
79. Waddell CC, JA Brown, YA Repinecz: Abnormal platelet function in myeloproliferative disorders. Arch Pathol Lab Med 105:432-435, 1981.
80. 2 receptors in platelets of patients with myeloproliferative disorder. J Clin Invest 64: 586-590, 1979.
81. Moore A, RL Nachman: Platelet Fc receptor: Increased expression in myeloproliferative disease. J Clin Invest 67:1064-1071, 1981.
82. Bolin RB, T Okumura, GA Jamieson: Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders. Am J Hematol 3:63-71, 1977.
83. Thibert V, S Bellucci, M Cristofari, et al: increased platelet CD36 constitutes a common marker in myeloproliferative disorders. Br J Haematol 91:618-624, 1995.
84. 4 versus ßTG as evidence for platelet activation in myeloproliferative disorders. Scand J Haematol 35:299-304, 1985.
85. Russell NH, J Salmon, JP Keenan, et al: Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res 22:389-397, 1981.
86. Pareti FI, L Gugliotta, L Mannuci, et al: Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemostas 47:84-89, 1982.
87. Okuma M, H Uchino: Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 54:1258-1271, 1979.
88. Schafer AI: Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 306:381-386, 1982.
89. Budde U, G Schaefer, N Mueller, et al: Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 64:981-985, 1984.
90. Raman BK, N Sawdyk, SM Saeed: Essential thrombocythemia with acquired von Willebrand's disease. Am J Clin Pathol 88:102-106, 1987.
91. Sato K: Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia. Keio J Med 37:54-71, 1988.
92. van Genderen PJJ, H Leenknegt, JJ Michiels: The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link? Semin Thromb Hemost 23:385-389, 1997.
93. Baker RI, A Manoharan: Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol 40:267-272, 1988.
94. Heptinstall S, SR Cockbill, ME Burgess-Wilson: Studies on platelets before and after stroke in a patient with essential thrombocythaemia. Br Med J 296:1298-1299, 1988.
95. Wehmeier A, T Südhoff, F Meierkord: Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 23:391-402, 1997.
96. Schafer AI: Management of thrombocythemia. Curr Opin Hematol 3:341-346, 1996.
97. Tefferi A, HC Hoagland: Issues in the diagnosis and management of essential thrombocythemia. Mayo Clin Proc 69:651-655, 1994.
98. Cortelazzo S, G Finazzi, M Ruggeri, et al: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.
99. Kwong YL, RH Liang, EK Chiu, et al: Essential thrombocythemia: a retrospective analysis of 39 cases. Am J Hematol 49:39-42, 1995.
100. Schafer AI: Primary and secondary thrombocytosis. In: Brain MC, PP Carbone (eds): Current Therapy in Hematology-Oncology. Mosby, St. Louis, 1995, pp 157-161.
101. Kaplan ME, K Mack, JD Goldberg, et al: Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 23:167-171, 1986.
102. Lofvenberg E, I Nordenson, A Wahlin: Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet 49:57-67, 1990.
103. Weinfeld A, B Swolin, J Westin: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Hematol 52:134-139, 1994.
104. Elliott MA, A Tefferi: Interferon-α therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemostas 23:463-472, 1997.
105. Gisslinger H, H Ludwig, W Linkesch, et al: Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1:634-637, 1989.
106. Tornebohm-Roche E, M Merup, D Lockner, et al: Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. Am J Hematol 48:163-167, 1995.
107. Tefferi A, MN Silverstein, RM Petitt, et al: Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 23:379-383, 1997.
108. Anagrelide Study Group: Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92:69-76, 1992.
109. Schrör K: Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23:349-356, 1997.
110. Griesshammer M, M Bangerter, F Herrmann, et al: Aspirin in essential thrombocythemia: Status quo and quo vadis. Semin Thromb Hemost 23:371-377, 1997.
111. Landolfi R, R Marchioli on hehalf of the ECLAP investigators: European collaboration on low-dose aspirin in polycythemia vera (ECLAP): A randomized trial. Semin Thromb Hemost 23:473-478, 1997.
112. Tartaglia AP, JD Goldberg, PD Berk, et al: Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172-176, 1986.